Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 376 AL 390

Dosimetry and Clinical Efficacy of Transcranial Photobiomodulation for Major Depression Disorder: Could they Guide Dosimetry for Alzheimer's Disease?

Caldieraro MA, Laufer-Silva T, Cassano P.

J Alzheimers Dis. 2021;83(4):1453-1469. doi: 10.3233/JAD-210586.

Evolution of genetic testing supports precision medicine for caring Alzheimer's disease patients

Bruni AC, Bernardi L, Maletta R.

Curr Opin Pharmacol. 2021 Oct;60:275-280. doi: 10.1016/j.coph.2021.08.004. Epub 2021 Sep 3.

Aducanumab (Aduhelm) for Alzheimer's disease

Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.

Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

Kehoe PG, Turner N, Howden B, Jarutyte L, Clegg SL, Malone IB, Barnes J, Nielsen C, Sudre CH, Wilson A, Thai NJ, Blair PS, Coulthard E, Lane JA, Passmore P, Taylor J, Mutsaerts HJ, Thomas DL, Fox NC, Wilkinson I, Ben-Shlomo Y; RADAR investigators.

Lancet Neurol. 2021 Nov;20(11):895-906. doi: 10.1016/S1474-4422(21)00263-5.

[Disease-modifying treatment approaches for Alzheimer's disease]

Frölich L, Hausner L.

Nervenarzt. 2021 Dec;92(12):1239-1248. doi: 10.1007/s00115-021-01222-w. Epub 2021 Nov 4.

From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease

Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB.

Cell. 2021 Nov 24;184(24):5886-5901.e22. doi: 10.1016/j.cell.2021.11.001.

Dementia with non-convulsive seizures: a case report

Chen YS, Chen TS, Huang CW.

J Int Med Res. 2021 Dec;49(12):3000605211062453. doi: 10.1177/03000605211062453.

Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease

Law CSW, Yeong KY.

Curr Med Chem. 2021;28(9):1716-1730. doi: 10.2174/0929867327666200312114223.

Connecting Mind-Body Therapy-Mediated Effects to Pathological Features of Alzheimer's Disease

Hüttenrauch M, Lopez-Noguerola JS, Castro-Obregón S.

J Alzheimers Dis. 2021;82(s1):S65-S90. doi: 10.3233/JAD-200743.

Implementing Delirium Prevention in the Era of COVID-19

Radhakrishnan NS, Mufti M, Ortiz D, Maye ST, Melara J, Lim D, Rosenberg EI, Price CC.

J Alzheimers Dis. 2021;79(1):31-36. doi: 10.3233/JAD-200696.

Update and Potential Opportunities in CBP [Cyclic Adenosine Monophosphate (cAMP) Response Element-Binding Protein (CREB)-Binding Protein] Research Using Computational Techniques

Akinsiku OE, Soremekun OS, Soliman MES.

Protein J. 2021 Feb;40(1):19-27. doi: 10.1007/s10930-020-09951-8. Epub 2021 Jan 4.

Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment

Pyun JM, Ryoo N, Park YH, Kim S.

Alzheimers Res Ther. 2021 Jan 5;13(1):10. doi: 10.1186/s13195-020-00749-5.

Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer's disease populations

Iodice F, Cassano V, Rossini PM.

Neurol Sci. 2021 Feb;42(2):455-465. doi: 10.1007/s10072-020-04902-8. Epub 2021 Jan 7.

Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities

Watts GF, Mamo JCL.

Clin Chem. 2021 Jan 8;67(1):6-8. doi: 10.1093/clinchem/hvaa294.

Crocus Sativus L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment

D'Onofrio G, Nabavi SM, Sancarlo D, Greco A, Pieretti S.

Curr Neuropharmacol. 2021;19(9):1606-1616. doi: 10.2174/1570159X19666210113144703.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias